FIGURE 2 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models

Tumor growth response to eribulin and copanlisib, either alone or in combination in WHIM29 and WHIM34. A, Tumor volume changes over time compared with that of day 1 after receiving either vehicle, eribulin (0.3 mg/kg i.p. on day 1 of each week × 4, except that 0.1 mg/kg eribulin was administered for the first two doses in WHIM29), copanlisib (10 mg/kg i.v. on days 2 and 3 each week × 4), or the combination of copanlisib and eribulin at the same dosing (n = 5 per group). B, Kaplan–Meier survival duration (days) of tumor-bearing mice after receiving treatments indicated in A. *, P P